Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000635067 | SCV000756445 | benign | Idiopathic generalized epilepsy; Hyperaldosteronism, familial, type IV | 2024-04-10 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002492971 | SCV002803988 | likely benign | Epilepsy, childhood absence, susceptibility to, 6; Hyperaldosteronism, familial, type IV | 2024-06-11 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004965618 | SCV005552802 | uncertain significance | Inborn genetic diseases | 2024-07-17 | criteria provided, single submitter | clinical testing | The c.3650G>A (p.R1217H) alteration is located in exon 17 (coding exon 16) of the CACNA1H gene. This alteration results from a G to A substitution at nucleotide position 3650, causing the arginine (R) at amino acid position 1217 to be replaced by a histidine (H). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |